Bisphosphonates are the most commonly used therapeutic agents for Paget's disease. Although bisphosphonates are effective in normalizing the biochemical markers that cause the erratic bone turnover ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

Please provide your email address to receive an email when new articles are posted on . An annual infusion of zoledronic acid was associated with less bone loss in ...

The oral bisphosphonate risedronate is currently used to treat patients with Paget's disease. Therapy, however, requires daily oral dosing for 2–6 months in a complex regimen that could result in ...

Reduction of pain as the primary determinant of improved quality of life of cancer patients receiving zoledronic acid (Zol) for bone involvement This is an ASCO Meeting Abstract from the 2005 ASCO ...

Researchers systematically consulted the Massachusetts General Hospital fracture liaison service for patients admitted to the orthopedics service with fragility fracture between February 2016 and ...

The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...

Impact of palliative care on end-of-life management of cancer patients dying in the hospital. Assessment of the current implementation and barriers to uptake of the guidelines for the psychosocial ...

GLASGOW, Scotland – A single infusion of zoledronic acid (Aclasta) prevents bone turnover in people at risk of Paget’s disease in an analysis of data from the Zoledronate in the Prevention of Paget’s ...

In general, IV bisphosphonates are very well tolerated, and patients rarely require dose modification. In the comparative phase 3 trial of zoledronic acid and pamidronate in patients with breast ...

EAST HANOVER, N.J., Oct. 16 /PRNewswire/ -- Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in ...

Eli Lilly and Company LLY today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months in postmenopausal women with osteoporosis, based on ...